Description:
XGEVA (denosumab) is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
XGEVA is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.
Cautions:
Hypocalcemia: Severe hypocalcemia can occur in patients receiving
Xgeva. Correct hypocalcemia prior to initiating Xgeva. Monitor
calcium levels and adequately supplement all patients with calcium and
vitamin D
Osteonecrosis of the jaw can occur in patients receiving Xgeva. Perform
an oral examination prior to starting Xgeva. Monitor for symptoms.
Avoid invasive dental procedures during treatment with Xgeva